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The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers heterogeneity
to some cancers beyond that explained by clonal evolution or environmental differences. In such cancers,
functional differences between tumorigenic and nontumorigenic cells influence response to therapy and
prognosis. However, it remains uncertain whether the model applies to many, or few, cancers due to ques-
tions about the robustness of cancer stem cell markers and the extent to which existing assays underesti-
mate the frequency of tumorigenic cells. In cancers with rapid genetic change, reversible changes in cell
states, or biological variability among patients, the stem cell model may not be readily testable.Sources of Heterogeneity within Cancer
Many tumors contain phenotypically and functionally heteroge-
neous cancer cells (Fidler and Hart, 1982; Fidler and Kripke,
1977; Heppner, 1984; Nowell, 1986). This heterogeneity among
cancer cells in the same patient can arise in multiple ways. The
most well-established mechanism involves intrinsic differences
among cancer cells caused by stochastic genetic (Nowell,
1976) or epigenetic (Baylin and Jones, 2011) changes (clonal
evolution; Figure 1A). Differences can also arise among cancer
cells through extrinsic mechanisms in which different microenvi-
ronments within a tumor confer phenotypic and functional differ-
ences upon cancer cells in different locations (Figure 1B) (Polyak
et al., 2009; Bissell and Hines, 2011). Finally, some cancers
follow a stem cell model in which tumorigenic cancer stem cells
‘‘differentiate’’ into nontumorigenic cancer cells, creating a hier-
archical organization (Figure 1C; Table 1) (Dick, 2008; Reya et al.,
2001; Shackleton et al., 2009). The differentiation of cancer stem
cells provides a mechanism for generating phenotypic and func-
tional heterogeneity beyond the heterogeneity that can be attrib-
uted to clonal evolution or environmental differences (Figure 1D).
However, the fact that heterogeneity can arise through multiple
mechanisms means that heterogeneity alone does not imply
the existence of a cancer stem cell hierarchy.
The Cancer Stem Cell Model
The cancer stem cell model is not a new idea (Hamburger and
Salmon, 1977). It has been clear for decades that some cancers,
including some germ lineage cancers (Kleinsmith and Pierce,
1964), some neuroblastomas (Shimada et al., 1984), and some
myeloid leukemias (Fearon et al., 1986; Ogawa et al., 1970),
can differentiate into progeny that have limited proliferative
potential despite retaining the oncogenic mutations of their
malignant progenitors.
Some germ lineage cancers contain rapidly dividing cells that
differentiate into postmitotic derivatives (mature teratoma
elements) in a process that resembles aberrant embryogenesis
(Chaganti and Houldsworth, 2000). The presence of only mature
differentiated cells in residual tumor masses after chemotherapy
is a favorable prognostic factor, while the presence of residualundifferentiated cells predicts disease recurrence (Stenning
et al., 1998). These and other data suggest that undifferentiated
cells are primarily responsible for tumor growth and disease
progression, consistent with the cancer stem cell model.
Neuroblastomas also exhibit variable degrees of differentia-
tion (Ambros et al., 2002; Shimada et al., 1999a, 1999b, 1984).
Neuroblastomas with widespread differentiation have a better
prognosis than those with limited differentiation (Shimada
et al., 1999b). Highly differentiated neuroblastic tumors are typi-
cally focal and can often be cured with surgery (Nitschke et al.,
1988). Conversely, poorly differentiated neuroblastomas are
often widely disseminated and are usually fatal despite aggres-
sive treatment (Matthay et al., 2009, 1999; Shimada et al.,
1999b). Therapies that promote differentiation significantly
improve survival (Matthay et al., 2009, 1999). In some infants,
disseminated tumors undergo spontaneous differentiation,
leading to a favorable outcome even without therapy (Baker
et al., 2010). While staging of neuroblastoma is complex and
involves a number of variables other than differentiation status,
these clinical observations are consistent with the cancer stem
cell model in suggesting that undifferentiated neuroblastoma
cells sometimes drive disease progression.
While the overt differentiation in some germ lineage cancers
and some neuroblastomas provided clinical evidence consistent
with the cancer stem cell model, these rare and unusual malig-
nancies are of uncertain relevance to more prevalent adult
cancers. Thus, the cancer stem cell model gained increased
attention when evidence emerged supporting the model in
leukemia and breast cancer. The advent of flow cytometry
made it possible to separate phenotypically distinct subpopula-
tions of live cancer cells to compare their tumorigenic potential.
Using this approach, some human acute myeloid leukemias
(AMLs) (Bonnet and Dick, 1997; Lapidot et al., 1994) and breast
cancers (Al-Hajj et al., 2003) were found to follow the cancer
stem cell model, suggesting that a broad spectrum of cancers
might be hierarchically organized into tumorigenic and nontu-
morigenic components. In each of these studies, cells capable
of forming leukemias/tumors were rare when transplanted into
immunocompromised mice but could be enriched by selectingCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 283
Figure 1. Sources of Heterogeneity within Cancer
(A) Heterogeneity can arise within tumors through stochastic genetic (Nowell, 1976) and epigenetic (Baylin and Jones, 2011) changes that confer heritable
phenotypic and functional differences upon cancer cells. This process is known as clonal evolution because the genetic/epigenetic changes are subject to
selection within tumors. This process tends to lead to more aggressive cancers over time; however, some cancer cells (gray) would be predicted to lose their
tumorigenic capacity as a consequence of disadvantageous genetic changes.
(B) Heterogeneity can arise in response to extrinsic environmental differences within tumors: cancer cells (blue) adjacent to blood vessels (red) are different from
cancer cells further from blood vessels (white) (Charles et al., 2010). The differences are shown as being reversible, though environmental differences could also
cause irreversible changes in cancer cell properties.
(C) Cancers that follow the stem cell model contain intrinsically different subpopulations of tumorigenic (red) and nontumorigenic cells (yellow and green)
organized in a hierarchy in which a minority population of tumorigenic cells gives rise to phenotypically diverse nontumorigenic cells. Nontumorigenic cells are
thought to compose the bulk of tumors but have little capacity to contribute to cancer progression (Dick, 2008; Reya et al., 2001; Shackleton et al., 2009).
Tumorigenic cells can be serially transplanted, re-establishing phenotypic heterogeneity with each passage.
(D) Cancers that follow the stem cell model are also subject to clonal evolution as well as heterogeneity from environmental differences within tumors. Thus, these
sources of heterogeneity are not mutually exclusive and may each apply to variable extents depending on the cancer.cells that expressed specific combinations of surface markers:
leukemia-initiating cells were CD34+CD38 (Bonnet and Dick,
1997; Lapidot et al., 1994) while breast cancer-initiating cells
were CD44+CD24/low (Al-Hajj et al., 2003). This suggested
that in some cancers only a small minority of cells can proliferate
extensively and that some therapies that shrink tumors might not
be curative because they fail to eliminate cancer stem cells.
Since these studies were published, other studies have taken
similar approaches to provide evidence that other human
cancers also follow the cancer stem cell model, including colon
cancer (Dalerba et al., 2007; O’Brien et al., 2007; Ricci-Vitiani
et al., 2007), pancreatic cancer (Li et al., 2007), brain tumors
(Bao et al., 2006; Piccirillo et al., 2006; Singh et al., 2004) and
ovarian cancer (Alvero et al., 2009; Curley et al., 2009; Stewart
et al., 2011; Zhang et al., 2008b). In each case, the capacity to
propagate the malignancy appeared to be restricted to a small,
phenotypically distinct subpopulation of cancer cells. In tumori-
genesis assays, many unfractionated cells had to be trans-
planted in order to transfer disease, suggesting that tumorigenic284 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.cells were rare. These studies suggested that many cancers
follow the stem cell model and might be more effectively treated
by targeting cancer stem cells.
Sources of Heterogeneity among Cancers
Despite these studies, the generalizability of themodel remained
uncertain. Does themodel apply to all cancers, or only some? Do
all AMLs and breast cancers follow the cancer stem cell model,
or only in certain patients? Differences among cancers in driver
mutations and in the cell-of-origin create great diversity in cancer
biology. Sometimes these differences are reflected in the histo-
pathology of the cancer, but in other cases they may influence
the underlying biology without recognized effects on histopa-
thology. Nonetheless, these sources of heterogeneity compli-
cate the testing of the cancer stem cell model and mean that
observations in a cancer from one patient may be true of cancers
in certain other patients, but not all patients.
Some cancers, including hierarchically organized cancers that
follow the stem cell model, can arise from normal stem cells
Table 1. Testing the Cancer Stem Cell Model
Properties of Cancers That Follow the Stem Cell Model
Experimental Evidence
Phenotypic and functional heterogeneity Flow cytometry distinguishes phenotypically distinct subpopulations of cancer cells that are
transplanted to test whether some are tumorigenic while others are nontumorigenic.
Hierarchical organization Cancer stem cells are tumorigenic cells that give rise to a hierarchy of tumorigenic and
nontumorigenic progeny. Upon transplantation, tumorigenic cells should give rise
to more tumorigenic cells as well as phenotypically distinct nontumorigenic cells.
Properties Sometimes Ascribed to Cancer Stem Cells but Not Required by the Model
Experimental Evidence
Therapy resistance Are tumorigenic cells more likely to survive therapy than nontumorigenic cells? Are tumorigenic
cells enriched by therapy?
Rarity Tumorigenic cells have been rare in many studies that supported the cancer stem cell model but,
in principle, such cells do not have to be rare in a hierarchically organized cancer.
Quiescence While cancer stem cells are sometimes claimed to be quiescent, little data support
this assertion and the cell cycle distribution of most cancer stem cells is unknown.
Asymmetric division Cancer stem cells are sometimes claimed to divide asymmetrically, but this has never
been demonstrated in vivo and cannot be an obligate property because it would
prevent the numerical expansion of cancer stem cells.
Derive from normal stem cells Experimentally, cancer stem cells can arise from either normal stem cells or from restricted
progenitors/differentiated cells. In practice, the cell-of-origin of most cancers is unknown.through mutations that overactivate self-renewal mechanisms
(Barker et al., 2009; Merlos-Sua´rez et al., 2011; Yang et al.,
2008). Other cancers, including hierarchically organized
cancers, can arise from restricted progenitors or differentiated
cells as a result of mutations that ectopically activate self-
renewal mechanisms in these cells (Figure 2A) (Cozzio et al.,
2003; Huntly et al., 2004; Krivtsov et al., 2006; Schu¨ller et al.,
2008; Yang et al., 2008; Zhao et al., 2010). Thus, hierarchical
organization in a cancer does not imply that it originated from
normal stem cells, and the cancer stem cell model does not
address the cell-of-origin (Wang and Dick, 2005). However, the
cell-of-origin can influence the hierarchical organization of
cancers as it influences the mutations that are competent to
transform (Wang et al., 2010). The interaction of driver mutations
with cellular context influences the frequency of leukemogenic
cells and perhaps the degree of hierarchical organization
(Heuser et al., 2009; Somervaille et al., 2009). Nonetheless, these
inferences are all based upon experimentally induced cancers.
The cell-of-origin for most cancers that spontaneously arise in
patients has not been identified, at least not with precision,
making it difficult to assess which biological differences among
human cancers reflect differences in cell-of-origin.
Spatial differences in the cell-of-origin can also influence
cancer properties. In some tissues, regional differences in
cellular properties influence the driver mutations that are compe-
tent to transform. Medulloblastomas can arise either from Sonic
Hedgehog pathway activation in granule neuron precursors of
the cerebellum or from Wnt pathway activation in dorsal brain-
stem progenitors (Gibson et al., 2010; Schu¨ller et al., 2008;
Yang et al., 2008) (Figure 2B). Medulloblastomas are hierarchi-
cally organized, consistent with the cancer stem cell model
(Read et al., 2009; Singh et al., 2004; Ward et al., 2009), so it is
likely that the regional identity of the cell-of-origin influences
cancer stem cell properties, though this has not yet been tested.
Ependymomas that arise from different regions of the central
nervous system have different mutations, different patterns ofgene expression, and different prognoses (Johnson et al.,
2010; Taylor et al., 2005). Because ependymomas appear to
arise from radial glia and are hierarchically organized into tumor-
igenic and nontumorigenic components (Taylor et al., 2005),
these results suggest that regional differences in radial glia
lead to regional differences in driver mutations and cancer
stem cell properties.
Temporal differences in the cell-of-origin also affect the prop-
erties of leukemogenic cells. Stem cell properties and self-
renewal mechanisms change with age (He et al., 2009; Levi
and Morrison, 2008). This likely alters the types of mutations
that are competent to initiate cancers. Consistent with this, the
mutation spectrum changes with age in human leukemias.
Some driver mutations are found primarily in older patients
(e.g., in FLT3, Nucleophosmin1, and Dnmt3a), whereas other
mutations occur throughout life (e.g., in Ras) or more commonly
in young patients (e.g., translocations involving AML1, MLL, and
NUP98) (Figure 2C) (Armstrong and Look, 2005; Berman et al.,
2011; Brown et al., 2007; Downing and Shannon, 2002; Falini
et al., 2005; Ho et al., 2011; Kiyoi et al., 1999; Kottaridis et al.,
2001; Ley et al., 2010; Meshinchi et al., 2001; Stirewalt et al.,
2001; Thiede et al., 2006; Vogelstein et al., 1990; Zwaan
et al., 2003). Because many AMLs are hierarchically organized
(Lapidot et al., 1994; Yilmaz et al., 2006) and driver mutations
influence the frequency of leukemogenic cells (Heuser et al.,
2009; Somervaille et al., 2009), temporal changes in the cell-of-
origin likely influence cancer stem cell properties.
Heterogeneity among Patients in Cancer Stem Cell
Phenotype
Differences in driver mutations and cell-of-origin among patients
raise the question of whether similar hierarchies of tumorigenic
and nontumorigenic cells, with similar markers, are conserved
among patients with similar cancers. Initial studies suggested
that AMLs in many patients adopted a similar hierarchical orga-
nization in which rare leukemogenic cells were distinguishedCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 285
Figure 2. Sources of Heterogeneity among Cancers
Differences in the cell-of-origin can directly and indirectly influence the
phenotype of tumorigenic cells and, perhaps, whether or not the cancer is
hierarchically organized.
(A) Different cell types in a stem/progenitor cell hierarchy within a normal tissue
may be transformed into cancer cells. The properties of the cell-of-origin
influence the types of mutations that are competent to transform and the
properties of the resulting cancer (Huntly et al., 2004; Wang et al., 2010).
(B) Spatial differences in the identity of the cell-of-origin within tissues influ-
ence the types of mutations that are competent to transform and the prop-
erties of the resulting cancer (Gibson et al., 2010; Johnson et al., 2010).
(C) Temporal differences in the cell-of-origin also influence the types of
mutations that are competent to transform and the properties of the resulting
cancer (J.A.M. and S.J.M., unpublished data), consistent with the observation
that the driver mutation spectrum changes with age in patients (Downing and
Shannon, 2002) (see text for references regarding age-related changes in the
incidence of specific mutations).from nonleukemogenic progeny by having a CD34+CD38
surface marker phenotype, largely irrespective of AML subtype
or blast cell maturation state (Bonnet and Dick, 1997; Lapidot
et al., 1994). Many studies from other laboratories went on to
characterize ‘‘leukemic stem cell’’ properties, such as gene
expression signatures, by isolating CD34+CD38 cells without286 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.verifying that these markers distinguished leukemogenic from
nonleukemogenic cells in the patients they studied.
It was subsequently determined that there are leukemia-
initiating cells among CD34 and CD38+ cells in some AMLs
(Sarry et al., 2011; Taussig et al., 2008, 2010). Dick and
colleagues systematically addressed this issue by comparing
the leukemogenic capacity of CD34+CD38, CD34+CD38+,
CD34CD38+, and CD34CD38 AML cells from 16 patients
(Eppert et al., 2011). In the 13 AMLs that engrafted, there was
leukemogenic activity in the CD34+CD38 fraction; however,
leukemogenic cells were also detected in at least one other frac-
tion in most patients. Most leukemogenic cells were contained in
the CD34+CD38 fraction in half of the patients and in the
CD34+CD38+ fraction in the other half of patients. In one case,
there were similar frequencies of leukemogenic cells in all frac-
tions, and a second case had leukemogenic cells in 3 of 4 frac-
tions. Leukemogenic activity is therefore not usually restricted
to the CD34+CD38 fraction and there is heterogeneity among
patients in leukemogenic cell phenotype (Figure 3). Some
AMLs might not follow the cancer stem cell model at all.
The frequency and phenotype of leukemogenic cells is also
highly variable in mouse AMLs. Deletion of Pten from adult
mouse hematopoietic cells leads to the development of AML
upon transplantation into wild-type mice (Yilmaz et al., 2006).
In these AMLs, leukemogenic activity is most highly enriched
among rare cells with a surface marker phenotype similar to
normal HSCs, but cells that express mature myeloid markers
possess lower levels of leukemogenic activity. Mouse AMLs
induced by MLL-AF9 expression appear to have much higher
frequencies of leukemogenic cells than observed after Pten
deletion (Krivtsov et al., 2006; Somervaille and Cleary, 2006;
Somervaille et al., 2009). In these leukemias, cells bearing
GMP-like surface markers have the highest frequency of leuke-
mogenic cells (Krivtsov et al., 2006); however, leukemogenic
activity is also found in other cell fractions (Somervaille and
Cleary, 2006; Somervaille et al., 2009). Differences in oncogenic
mutations can thus have profound effects on the frequency and
phenotype of leukemia-initiating cells.
The same is true in solid cancers. Tumorigenic cells are en-
riched within the CD44+CD24/low population of some breast
cancers (Al-Hajj et al., 2003). However, other breast cancers
studied by Al-Hajj et al. had more phenotypically diverse breast
cancer-initiating cells, demonstrating that the CD44+CD24/low
surface marker phenotype does not universally distinguish
tumorigenic from nontumorigenic breast cancer cells (Al-Hajj
et al., 2003). In mouse models of mammary cancer, different
driver mutations give rise to cancers that differ in the extent to
which they follow the stem cell model (Cho et al., 2008; Vaillant
et al., 2008; Zhang et al., 2008a); for example, CD61 enriched
for cancer stem cell activity in mice with Wnt1 driven breast
cancers but not in mice with Neu/ErbB2 driver breast cancers
(Vaillant et al., 2008). Mouse models of lung cancer with different
transforming mutations have tumorigenic cells with different sur-
face marker phenotypes (Curtis et al., 2010). Thus, different
oncogenic mutations give rise to cancers that differ in the extent
to which they follow the cancer stem cell model and in tumori-
genic cell phenotype.
These results demonstrate the importance of testing cancer
stem cell markers in significant numbers of patients to
Figure 3. Variation among Leukemias in the
Degree and Nature of Hierarchical
Organization
Although most AMLs follow a cancer stem cell
model, the surface marker phenotypes of the
leukemogenic cells vary from patient to patient.
(A–C) Different oncogenic mutations can trans-
form cells at different levels within the hemato-
poiesis hierarchy (Wang et al., 2010), potentially
influencing the frequency, spectrum, and pheno-
type of cells with leukemogenic potential. Inter-
conversion between leukemogenic cell pop-
ulations would allow any population to recapitulate
the heterogeneity of the leukemogenic cell pool
(Eppert et al., 2011; Sarry et al., 2011).
(D) Some mutations, such as MLL-AF9 trans-
locations, can confer leukemogenic activity upon
restricted progenitors (Cozzio et al., 2003; Huntly
et al., 2004; Krivtsov et al., 2006; Zhao et al., 2010).
(E) If multiple populations have leukemogenic
capacity but do not interconvert, then only the
most immature cells can recapitulate the full
heterogeneity of the parent leukemia, but multiple
levels of the hierarchymay be able to drive disease
progression (Goardon et al., 2011).
(F) In some ALLs, many cells have leukemogenic
activity despite heterogeneity in marker expres-
sion (le Viseur et al., 2008; Williams et al., 2007).appreciate the heterogeneity among patients. Yet studies of
cancer stem cell characteristics often assume that markers iden-
tified in one study can be applied without validation to other
patients, to cell lines, or to cells transformed in culture. The
conclusions in such studies may be undermined by heteroge-
neity among patients or by context- or oncogene-dependent
effects on tumorigenic cell phenotype.
The Implications of the Cancer Stem Cell Model
for Therapy
In cancers that follow the stem cell model, the functional differ-
ences between tumorigenic and nontumorigenic cells can have
important implications for therapy. For example, the BCR-ABL
inhibitor imatinib has been incredibly effective at restoring the
health and prolonging the lives of patients with chronic myeloid
leukemia (CML) (Druker et al., 2006); however, these patients
must remain on imatinib indefinitely because many patients fail
to completely eliminate BCR-ABL-expressing cells from their
bone marrow (Bhatia et al., 2003; Chu et al., 2011) and even
patients that achieve a complete molecular remission often
relapse upon withdrawal of therapy (Rousselot et al., 2007).Cancer Cell 2These clinical observations appear to
be explained by the persistence of rare
imatinib-resistant CML stem cells (Chu
et al., 2011; Graham et al., 2002; Holtz
et al., 2002). A mouse model of CML-
like disease driven by HIP1-PDGFR and
AML1-ETO fusion proteins had leukemo-
genic and nonleukemogenic subpopula-
tions of cancer cells distinguished by
differences in surface marker expression
(Oravecz-Wilson et al., 2009). The leuke-
mogenic cells were rare and much more
resistant to imatinib than their nonleuke-mogenic progeny. Imatinib treatment dramatically enriched
leukemogenic cells despite reducing overall leukemia burden.
Evidence has also been presented for radiation resistance in
brain tumor-initiating cells (Bao et al., 2006) and breast cancer-
initiating cells (Diehn et al., 2009).
While it has become fashionable to consider therapy resis-
tance a defining feature of cancer stem cells, the sensitivity of
tumorigenic and nontumorigenic cells to therapy depends
upon the cancer and the therapy. Some therapies actually
exploit the capacity of tumorigenic cells to differentiate into non-
tumorigenic cells by inducing differentiation. Acute promyelo-
cytic leukemia is treated with arsenic trioxide and trans-retinoic
acid, which induce rapid terminal differentiation, growth arrest,
and apoptosis of the cancer cells (de The´ and Chen, 2010).
Differentiation therapy has also been exploited experimentally
in glioblastoma by treating with bone morphogenetic protein 4
(BMP4) to induce glial differentiation, reducing proliferation,
tumor growth, and tumorigenic cell frequency (Piccirillo et al.,
2006). BMP4 also promotes glial differentiation by normal CNS
stem cells (Gross et al., 1996) suggesting tumorigenic cancer
cells sometimes inherit differentiation pathways from normal1, March 20, 2012 ª2012 Elsevier Inc. 287
stem cells in the same tissue. Cis-retinoic acid also induces glial
differentiation and improves survival in high-risk neuroblastoma
patients (Matthay et al., 1999; Thiele et al., 1985). Thus, tumori-
genic cells are specifically targeted by some therapies.
Therapy resistance can also arise through genetic mecha-
nisms that are not necessarily related to cancer stem cells. While
the intrinsic resistance of CML-initiating cells to imatinib allows
these cells to persist in treated patients who are in remission,
the ongoing administration of imatinib generally prevents relapse
until the CML-initiating cells acquire an amplification of BCR-
ABL or point mutations that confer imatinib resistance (Gorre
et al., 2001; Roumiantsev et al., 2002). Melanomas carrying
V600E BRAF mutations become resistant to the BRAF inhibitor
vemurafenib through a variety of genetic mechanisms (Johan-
nessen et al., 2010; Nazarian et al., 2010; Poulikakos et al.,
2011; Poulikakos and Rosen, 2011; Villanueva et al., 2010),
and we are unable to find any evidence that melanoma follows
a cancer stem cell model (Quintana et al., 2010; Quintana
et al., 2008). Therefore, cancer progression and therapy resis-
tance may be influenced by the properties of cancers stem cells
in cancers that follow the model, but therapy resistance and
disease progression can also arise through genetic changes
unrelated to the question of whether a cancer follows the stem
cell model.
Tumorigenesis Assays
The xenotransplantation of human cancer cells into mice differs
in a number of important respects from the growth of human
cancer cells in patients. Mouse tissues differ from human tissues
in terms of architecture and stromal cells (Kuperwasser et al.,
2004). Mouse growth factors and adhesion molecules some-
times do not bind human receptors (Manz, 2007). Autologous
immune cells are an important element of the tumor microenvi-
ronment as they can either promote or impair tumor growth (de
Visser et al., 2006). Yet there are profound differences in immune
regulation between the autologous and xenogeneic settings.
Human cells transplanted into mice are subject to powerful
xenogeneic immune responses that kill most human cells before
they have an opportunity to proliferate (Auchincloss and Sachs,
1989). That is why human cancer cells must be transplanted
into highly immunocompromised mice to assay tumorigenic
capacity. Even NOD/SCIDmice retain an attenuated xenogeneic
barrier. Transplantation into more highly immunocompromised
mice (such as NOD/SCID IL2Rgnull) can significantly increase
the frequency of tumorigenic cells that is detected in some, but
not all, human cancers (Ishizawa et al., 2010; Kennedy et al.,
2007; Quintana et al., 2008).
Some have speculated that less immunocompromised mice
may represent ‘‘better models’’ for studying human cancers
because the preservation of some immune activity makes these
mice more similar to patients. However, the mechanisms by
which mouse immune cells respond to transplanted human cells
bear little resemblance to the mechanisms by which human
immune cells sometimes respond to autologous cancer cells
(Auchincloss and Sachs, 1989). No xenotransplantation assay
can model the immune responses that sometimes occur in
patients against their own tumors. Normal human hematopoietic
stem cells (HSCs) and cancer-initiating cells are therefore more
likely to be detected in more highly immunocompromised288 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.mice: NOD/SCID mice treated with anti-CD122 antibody to
deplete NK cells or NOD/SCID IL2Rgnull mice (Eppert et al.,
2011; McDermott et al., 2010; Quintana et al., 2008).
It is also critical to recognize that transplantation assays,
particularly xenotransplantation assays, test the potential of cells
to form tumors, not their actual fate in the tumor in which they are
born (Figure 4). There are many environmental variables in the
tumor environment, such as hypoxia and immune responses,
which can prevent cells that have the potential to form a tumor
from actually doing so in their normal environment. Conse-
quently, nobody knows whether many, or few, cells with tumor-
igenic potential actually contribute to disease progression in
patients. The question of which cells are actually fated to
contribute to disease progression is highly context dependent
and is probably not testable in patients because of the experi-
mental manipulations that would be required; however, this is
testable by fate mapping of cells in mouse tumors. It will be inter-
esting to compare the results of side-by-side fate-mapping
experiments and transplantation assays to assess whether the
cells that have the potential to form tumors upon transplantation
are the same cells that drive disease progression in situ.
Tumorigenic Cells Are Abundant in Some Cancers
Not all hematopoietic malignancies contain rare cancer-initiating
cells. Tumorgenic/leukemogenic cells are common in certain
mouse models of B cell lymphoma, T cell lymphoma, and AML
in which it is possible to transfer disease to wild-type recipients
by transplanting only ten cells (Kelly et al., 2007). In a mouse
model of B cell acute lymphoblastic leukemia (ALL), at least
50% of cancer cells are capable of transferring disease into
wild-type recipient mice (Williams et al., 2007). In these malig-
nancies, the abundance of tumorgenic/leukemogenic cells
suggests that if there is any hierarchy it must be much more
shallow than observed in many human AMLs, which so far
have consistently appeared to have rare leukemogenic cells
(Bonnet and Dick, 1997; Lapidot et al., 1994).
Tumorigenic cells are also common in some human cancers.
When human melanomas were first transplanted into NOD/
SCID mice, it was estimated that only one in a million melanoma
cells were capable of forming tumors, and melanoma was
proposed to follow a cancer stem cell model (Schatton et al.,
2008). However, simple changes in tumorigenesis assay condi-
tions (including the use of NOD/SCID IL2Rgnull mice) increased
the detected frequency of tumorigenic cells to one in four (Quin-
tana et al., 2008).We now routinely transplant single cells directly
from patients into NOD/SCID IL2Rgnull mice and on average
30% of single cells form tumors (Quintana et al., 2010). We
have quantified the frequency of tumorigenic cells from more
than 30 patients with diverse stages and sites of disease, and
in every case, the frequency of tumorigenic cells has been
high, even in primary cutaneous melanomas obtained directly
from patients (Quintana et al., 2010). Similar results have been
published with mouse models of melanoma (Held et al., 2010).
Thus, xenotransplantation assays sometimes dramatically
underestimate the frequency of human cancer cells with tumor-
igenic potential.
Is melanoma unique among solid cancers in having common
tumorigenic cells?We addressed this question in mouse models
of malignant peripheral nerve sheath tumors (MPNSTs)
Figure 4. Fate versus Potential in Cancer
(A) Potential describes what cells can do in a permissive environment. The
cancer stem cell model, and the transplantation assays (black arrows) on
which it is largely based, address the potential of cancer cells to form tumors.
(B) Fate reflects what cells actually do in a specific environment. In the context
of cancer, the question is which cells are fated to contribute to tumor growth
and disease progression in their actual environment in the patient. Many of the
cells that have the potential to form tumors upon transplantation may not be
fated to contribute to disease progression in a particular patient because they
are not in a permissive environment. For example, some cancer cells undergo
cell death due to hypoxia or immune effector activity. Some of these cells
might have the potential to form a tumor if transplanted into another environ-
ment, but are fated to undergo cell death in the tumor environment in which
they actually reside in the patient. Theremay also be cells that lack the ability to
form a tumor upon transplantation but that are nonetheless fated to contribute
to disease progression in the patient, such as if they acquire a new mutation
that increases their proliferation. Transplantation assays only assess potential,
not fate, in a patient and therefore should attempt to detect the full range of
cells with the potential to form tumors. No transplantation assay mimics the
environment within patient tissues and such assays are neither designed nor
capable of assessing cell fate in patients. Consequently, very little is known
about the spectrum of cells fated to contribute to tumor growth and disease
progression in patients or the extent to which it overlaps with the spectrum of
cells that can form a tumor upon transplantation.(Buchstaller et al., 2012). We found that approximately 20% of
mouse MPNST cells have the potential to form tumors, even
when transplanted into fully immunocompetent mice. This
suggests that tumorigenic cells may be common in a numberof solid cancers, though it is important to note that we have
not tested whether MPNSTs are hierarchically organized, and
therefore, it is unknown whether this cancer has a shallow hier-
archical organization.
An important question is whether we have systematically
underestimated the frequency of tumorigenic cells by using
transplantation assays that have not been optimized to detect
the full range of cells with the potential to form tumors. Work
on human HSCs and AML has identified numerous assay
improvements that increased estimates of stem cell frequency
by orders of magnitude (Eppert et al., 2011; Kennedy et al.,
2007; McDermott et al., 2010; McKenzie et al., 2005; Notta
et al., 2010), but assays for tumorigenic cells from solid cancers
generally have not been studied to the same extent. Enzymatic
dissociation conditions, sorting conditions, transplantation site,
the extracellular matrix environment, and the recipient mouse
(sex and strain) all affect the ability to detect tumorigenic cells.
Other undiscovered assay parameters may also be important.
Estimates of tumorigenic cell frequencies may continue to
increase in many cancers as assays improve, though tumori-
genic cells will likely remain rare in some cancers despite such
improvements (Eppert et al., 2011; Ishizawa et al., 2010).
Do Tumorigenesis Assays Test the Ability to
Recapitulate Tumor Heterogeneity?
A fundamental element of the stem cell model is that cancer stem
cells give rise to phenotypically diverse progeny that recapitulate
the heterogeneity of the tumor from which they derive
(Figure 1C). This is presumed to occur through epigenetic mech-
anisms akin to the differentiation of normal stem cells; however,
nobody has experimentally confirmed that epigenetic differ-
ences distinguish tumorigenic from nontumorigenic cells. The
differentiation of cancer stem cells into nontumorigenic progeny
is commonly assumed to be the major driver of heterogeneity in
cancers that follow the stem cell model; however, the degree of
genetic heterogeneity in such cancers is unknown. Therefore,
some of the phenotypic and functional differences among
cancer cells that have been attributed to the differentiation of
cancer stem cells might derive from genetic differences that
arise through clonal evolution (Figure 5A).
Since genetic changes are irreversible and stochastic, no
tumorigenic cell can recapitulate the genetic heterogeneity of
the tumor from which it derives. If the degree of genetic hetero-
geneity within a tumor is low, then cancer stem cells may be able
to largely recapitulate the heterogeneity of the tumors from
which they derive by differentiating into nontumorigenic cells
(Figure 5B). However, if there is extensive genetic heterogeneity,
then every tumorigenic cell may form a genetically distinct tumor
and no tumorigenic cell will recapitulate the heterogeneity of the
primary tumor (Figure 5C). Increasing evidence suggests that
there is more genetic heterogeneity within tumors than previ-
ously thought (Navin et al., 2011; Yachida et al., 2010). However,
driver mutations are rare among the genetic changes observed
in cancer, so the degree of genetic heterogeneity that influences
cancer cell function may be more modest. Nonetheless, if there
is widespread genetic heterogeneity, functional and phenotypic
differences among cancer cells cannot be assumed to be driven
by epigenetic hierarchies rather than genetic differences (Camp-
bell et al., 2010; Ding et al., 2010).Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 289
Figure 5. The Influences of Genetic Change and Reversible Transitions in Cell States on Hierarchical Organization in Cancer
(A) According to the clonal evolution model, many cancer cells have tumorigenic potential (circular self-renewal arrows) and heterogeneity arises through
stochastic genetic/epigenetic changes (lightning bolt). Changes in cell phenotype are not necessarily associated with changes in tumorigenic potential.
(B) For cancers that follow a stem cell model in which only the cells at the top of the hierarchy retain tumorigenic capacity, the differentiation of these cells into
nontumorigenic progeny creates tumor heterogeneity. Differentiation is associated with a loss of tumorigenic potential.
(C) For cancers with a high rate of genetic change, clones of cells within the hierarchy depicted in (B) may acquire tumorigenic potential as a consequence of new
mutations. Phenotypic changes are sometimes associated with changes in tumorigenic potential and sometimes not. Note that it would be difficult to experi-
mentally distinguish this model from the model in (A).
(D) A cancer that is hierarchically organized according to the cancer stem cell model but in which nontumorigenic cells can inefficiently revert to higher levels of the
hierarchy. In this case, tumorigenic cells could be enriched or depleted using markers but ‘‘nontumorigenic’’ cells from the bottom of the hierarchy would always
retain some tumorigenic capacity due to their ability to revert to tumorigenic states.
(E) A hierarchically organized cancer in which cells readily and reversibly interconvert between tumorigenic (red) and nontumorigenic (yellow and green) states.
Note that it would be difficult to experimentally distinguish case (E) from case (C). In cancers that are genetically unstable or subject to efficient reversible cell
transitions, the cancer stem cell model may be untestable, because it may be difficult to experimentally distinguish from cancers in which there is no hierarchy but
where heterogeneity arises through clonal evolution.
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In cancers that follow the stem cell model, cancer stem cells
would be expected to undergo genetic change over time.
Consistent with this, leukemia-initiating cells in B-ALLs undergo
clonal evolution (Anderson et al., 2011; Notta et al., 2011),
though these studies did not test whether the B-ALLs were hier-
archically organized according to the cancer stem cell model. In
cancers that do not follow the cancer stem cell model, genetic
change would also occur over time and would be predicted
to introduce phenotypic and functional heterogeneity. Thus,
the cancer stem cell and clonal evolutionmodels can be interact-
ing, or independent, sources of heterogeneity depending on the
cancer.
Another issue concerns the extent to which existing assays
reliably test phenotypic heterogeneity. Some have suggested
that melanomas have intrinsically different populations of tumor-
igenic and nontumorigenic cells that can be distinguished based
on ABCB5 (Schatton et al., 2008) or CD271 (Civenni et al., 2011;
Boiko et al., 2010) expression. However, neither of these
markers correlate with the frequency of tumorigenic cells, and
in our hands, small numbers of cells that are positive or negative
for ABCB5 or CD271 have a similar capacity to form tumors and
to recapitulate the phenotypic heterogeneity of the tumors from
which they derive (Quintana et al., 2010). We also identified 20
other markers that are heterogeneously expressed by human
melanoma cells and transplanted just 10 cells that were either
positive or negative for each of these markers into NOD/SCID
IL2Rgnull mice (Quintana et al., 2010). All subpopulations ex-
hibited a similar capacity to form phenotypically heterogeneous
tumors. Thus, we have subdivided melanomas from many
patients into almost 50 subpopulations of cells based on differ-
ences in marker expression and have not found any subpopula-
tion that lacks the ability to form a phenotypically heterogeneous
tumor.
The simplest interpretation of our data (Quintana et al., 2010)
and other data (Pinner et al., 2009; Roesch et al., 2010) is that
melanoma cells are phenotypically plastic, reversibly turning
on and off markers. In contrast, Civenni et al. reported that
both CD271+ and CD271 melanoma cells formed tumors in
NOD/SCID IL2Rgnull mice but that the tumors formed by
CD271 cells were not heterogeneous for CD271 expression
and that only CD271+ cells formed tumors in NOD/SCID mice
(Civenni et al., 2011). They speculated that the difference relative
to our results reflected different dissociation conditions. In our
hands, both dissociation methods yield similar results with
CD271+ and CD271 melanoma cells each forming heteroge-
neous tumors that can be serially passaged, irrespective of
whether they are transplanted in to NOD/SCID or NOD/SCID
IL2Rgnull mice (E. Quintana, U. Eskiocak, and S.J.M., unpub-
lished data); however, if differences in enzymatic dissociation
methods in solid cancers can sometimes generate reproducible
differences in the phenotype of tumorigenic cells, this would
illustrate the complexity of reproducing ‘‘cancer stem cell’’
markers.
If there are certain cells that reproducibly form tumors in NOD/
SCID IL2Rgnull mice and reproducibly fail to form tumors in NOD/
SCID mice, what would this mean? Are some human cells more
able to evade rejection by mouse immune cells? If so, does this
have any physiological relevance for these cells in humans? If
some tumorigenic cells aremore able to generate phenotypicallyheterogeneous progeny than others, what does this mean?
Could this reflect genetic differences among the cells (Campbell
et al., 2010; Ding et al., 2010) rather than hierarchical epigenetic
differences? Ultimately, a cell that has the potential to form
a tumor in any assay has the potential to contribute to disease
progression in a patient and cannot be ignored during therapy.
Uncertainty in Cancer Stem Cell Markers
In some cases, it has proven difficult to confirm markers that
originally appeared to robustly distinguish tumorigenic from non-
tumorigenic cells; for example, CD133 was reported as a marker
of tumorigenic brain cancer cells, and even large numbers of
CD133-negative brain tumor cells were reported to lack the
ability to form tumors (Bao et al., 2006; Singh et al., 2004). On
this basis, gliomas and medulloblastomas were concluded to
follow a cancer stem cell model. Yet subsequent studies found
tumorigenic activity among both CD133+ and CD133 brain
tumor cells (Beier et al., 2007; Chen et al., 2010; Joo et al.,
2008; Wang et al., 2008). These discrepancies could reflect
differences among patients, methodological differences among
laboratories, or ascertainment/tumor selection bias that led early
studies to overestimate the robustness of markers. Work with
other markers continues to support the conclusion that gliomas
and medulloblastomas follow a cancer stem cell model (Read
et al., 2009; Son et al., 2009; Ward et al., 2009); however, to
confirm the existence and identity of cancer stem cells, it is
necessary to identify markers that reproducibly distinguish
tumorigenic and nontumorigenic cells, at least in specific
subsets of patients.
Tumorigenic ovarian cancer cells have been reported to be en-
riched in the CD44+ (Alvero et al., 2009), CD44+CD117+ (Zhang
et al., 2008b), and CD133+ (Curley et al., 2009) subpopulations
of ovarian cancer cells. However, when Stewart et al. evaluated
a large cohort of ovarian cancers, they were unable to find
CD44+CD117+ cells in most ovarian cancers and the
CD44+CD117+ cells they did find were depleted for tumorigenic
activity (Stewart et al., 2011). CD133 enriched tumorigenic
ovarian cancer cells in some cases and not in other cases.
CD133 expression changed on some tumorigenic cells during
passaging (Stewart et al., 2011). This suggests that CD133
only marks ovarian cancer stem cells under defined conditions
in some patients and that the hierarchical organization of some
ovarian cancers is not stable. It remains uncertain what fraction
of ovarian cancers follow the stem cell model.
Cancer stem cell markers have proven difficult to broadly
confirm in a number of solid cancers, raising questions about
whether we have overestimated the number of cancers that
follow this model and making it difficult to study the biology of
these cells. Alternatively, it is possible that many cancers are
hierarchically organized but that there is considerable diversity
among patients in terms of the markers that distinguish tumori-
genic from nontumorigenic cells. This is a key issue that must
be resolved and which may require approaches other than the
traditional dependence upon cell surface markers. For example,
the separation of live cancer cells based on functional measures,
such as signaling pathway activation (Vermeulen et al., 2010),
might reduce phenotypic variability among tumorigenic cells.
Unfortunately, the genetic approaches currently required to do
this are only possible in mice where the use of inbred geneticCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 291
backgrounds and targeted mutations already reduce variability
in cancer models relative to what is observed in patients.
Do Nontumorigenic Cells Sometimes Form Tumorigenic
Cells?
Recent studies have suggested that the differentiation of cancer
stem cells into nontumorigenic cells may be reversible (Chaffer
et al., 2011; Gupta et al., 2011). In culture, immortalized human
mammary epithelial cells (HMECs) undergo an epithelial-
to-mesenchymal transition (EMT) following sustained expres-
sion of the transcription factors Snail or Twist, silencing of
E-cadherin, or exposure to TGF-b (Mani et al., 2008; Morel
et al., 2008; Scheel et al., 2011). This EMT was interpreted as
conferring stem cell properties upon normal or transformed
epithelial cells in culture, partly because the cells acquired
a CD44+CD24 phenotype, similar to breast cancer stem cells.
The idea that cancer cells might reversibly transition between
epigenetically defined tumorigenic and nontumorigenic states
is appealing, partly because mechanisms that generate revers-
ible heterogeneity can confer therapy resistance (Roesch et al.,
2010; Sharma et al., 2010). However, it is not clear whether
CD44 and CD24 consistently distinguish tumorigenic from non-
tumorigenic cells in cultured cell lines or whether nontumorigenic
cells acquire tumorigenic potential by EMT in breast cancers
in vivo.
The idea that nontumorigenic cancer cells could sometimes
revert to having tumorigenic capacity is plausible given that
restricted progenitors dedifferentiate into stem cells in certain
normal tissues. In theDrosophila testis andovary, spermatogonia
and cytocytes dedifferentiate into germline stem cells under
certain circumstances (Brawley and Matunis, 2004; Kai and
Spradling, 2004). In mouse testis, spermatogonial progenitors
can also dedifferentiate into spermatogonial stem cells (Barroca
et al., 2009). So far this dedifferentiation has only been observed
in normal tissues at low frequencies or under restricted circum-
stances. Nonetheless, if nontumorigenic cancer cells revert to
a tumorigenic state at an appreciable rate in certain cancers,
then this would undermine the ability to distinguish tumorigenic
from nontumorigenic cells as even the ‘‘nontumorigenic’’ cells
would be expected to form tumors at some level.
It is not clear whether the cancer stem cell model would effec-
tively describe cancers in which there are tumorigenic and non-
tumorigenic states that can reversibly interconvert. If cells in the
nontumorigenic state only convert to the tumorigenic state under
restricted circumstances or with low efficiency, then it may still
be possible to identify markers that distinguish populations
that are enriched or depleted for tumorigenic capacity
(Figure 5D). However, if cells in the nontumorigenic state convert
to the tumorigenic state with high efficiency, it should not be
possible to distinguish tumorigenic from nontumorigenic cells,
potentially rendering the cancer stem cell model untestable in
such cancers (Figure 5E). New models may be required to
describe the heterogeneity in such cancers.
Cancer Stem Cells and Metastasis
Metastasis requires cells from a primary tumor to detach, invade
the vascular or lymphatic system, migrate to distant sites,
extravasate, then proliferate extensively and recruit new vascu-
lature (Nguyen et al., 2009). There is much discussion regarding292 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.the metastasis of cancer stem cells, though nobody has actually
tested whether the cells that are enriched for tumorigenic activity
in transplantation assays are also enriched for the capacity to
metastasize under physiological conditions. A fundamental
question is whether metastatic potential is confined to a single
population of tumorigenic cells or whether it arises stochastically
through genetic or epigenetic changes that occur inmany cancer
cells without regard to their competence to form tumors prior to
the stochastic change.
Some studies have suggested that subpopulations of tumori-
genic pancreatic cancer (Hermann et al., 2007) and colon cancer
(Pang et al., 2010) cells are enriched for the capacity to metasta-
size. However, the relationship between tumorigenic cells and
metastasis has not yet been addressed systematically by exam-
ining all of the cancer cells that can be found in circulation and
their tumorigenic capacity. Therefore, it remains uncertain
whether nontumorigenic cancer cells have a similar capacity to
disseminate as tumorigenic cells, or whether nontumorigenic
cells from a primary tumor can sometimes acquire tumorigenic
capacity after migrating to a new environment.
It has been proposed that cancer cells acquire metastatic
potential by undergoing an EMT (Kalluri and Weinberg, 2009).
As cancer cells lose their epithelial characteristics, they lose
intracellular adhesions and polarity while acquiring more mesen-
chymal features such as the ability to migrate, invade, and
resist apoptosis (Thiery et al., 2009). EMT has been proposed
as a requisite step for breast cancer metastasis (Yang et al.,
2004) and induction of an EMT also confers upon cultured
cells a surface marker phenotype (CD44+CD24) similar to
tumorigenic breast cancer cells (Mani et al., 2008; Scheel
et al., 2011). If cancer cells that have no tumorigenic capacity
in transplantation assays can acquire this potential by under-
going an EMT, then any cancer cell could acquire metastatic
potential.
Although the cancer stem cell model and work on EMTs focus
on epigenetic differences between tumorigenic and nontumori-
genic cells, there is good evidence that irreversible geneticmuta-
tions also confer metastatic potential (Vogelstein et al., 1988). In
pancreatic cancer and medulloblastoma, genetically distinct
subclones initiate metastatic disease (Campbell et al., 2010;
Wu et al., 2012; Yachida et al., 2010). This raises the question
of whether only cancer stem cells are competent to acquire
genetic changes that confer metastatic potential or whether non-
tumorigenic cells can acquire genetic changes that confer both
tumorigenic and metastatic potential. These fundamental ques-
tions remain to be studied in primary tumors in vivo, so the impli-
cations of the cancer stem cell model for metastasis are unre-
solved.
Conclusions and Future Directions
 Some cancers are hierarchically organized into undifferen-
tiated cells that can drive disease progression and differen-
tiated cells with less capacity to drive disease progression,
consistent with the cancer stem cell model.
 Cancers that exhibit this kind of hierarchical organization
have functional differences among undifferentiated and
differentiated cancer cells that affect response to therapy
and prognosis.
 There remain a number of uncertainties that make it difficult
to assess whether many, or few, cancers follow the stem
cell model. Some ‘‘cancer stem cell’’ markers have proven
difficult to confirm, and tumorigenic cell frequencies can
sometimes increase dramatically as a result of changes in
assay conditions.
 Many studies have assumed that markers discovered in
earlier studies were universally able to distinguish tumori-
genic from nontumorigenic cells, even in independent
patient cohorts or in cultured cell lines. Given the heteroge-
neity that is evident among patients and the context depen-
dence of some markers, ‘‘cancer stem cell’’ markers
should be confirmed in functional assays in each patient
or under each experimental circumstance in which they
are used.
 It remains unclear to what extent we have systematically
underestimated tumorigenic cell frequencies by using
assays that are not optimized for the engraftment of trans-
planted cells. In some cases, the underestimates may be
modest and may not affect conclusions. In other cases,
cancers thought to have only rare tumorigenic cells may
actually have common tumorigenic cells.
 It will be necessary to systematically assess the degree to
which changes in assay conditions affect the spectrum of
cancer cells that can form tumors. If a cancer cell has the
potential to proliferate extensively in any assay, then it
has the potential to contribute to disease progression,
and it is perilous to ignore that cell during therapy.
 It will be important to fate map cells within tumors thought
to follow the cancer stem cell model to test whether only
small populations of phenotypically distinct cells actually
promote tumor growth and disease progression.
 Few studies have assessed the degree of genetic hetero-
geneity among cancer cells within the same tumor or the
extent to which this causes phenotypic and functional
differences. In some cancers, genetic heterogeneity may
confound the assumption that heterogeneity arises from
hierarchical epigenetic differences, rendering the cancer
stem cell model difficult to test.
 It will be important to test whether primary tumors in vivo
contain cells that reversibly transition between tumorigenic
and nontumorigenic states. The cancer stem cell model
may not effectively describe cancers in which the efficiency
of interconversion is high.
 It will be necessary to distinguish cancers that follow the
stem cell model from those that do not to avoid testing
agents that target specific subpopulations of cancer cells
in patients who have no chance of benefitting from them.ACKNOWLEDGMENTS
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